IRadimed Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US46266A1097
USD
93.92
1.86 (2.02%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About IRadimed Corp. stock-summary
stock-summary
IRadimed Corp.
Pharmaceuticals & Biotechnology
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.
Company Coordinates stock-summary
Company Details
1025 Willa Springs Dr , WINTER SPRINGS FL : 32708-5235
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 56 Schemes (17.33%)

Foreign Institutions

Held by 59 Foreign Institutions (4.92%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Roger Susi
Chairman of the Board, President, Chief Executive Officer, Founder, Chief Technology Officer
Mr. Monty Allen
Independent Director
Mr. James Hawkins
Independent Director
Mr. Anthony Vuoto
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
20 Million
(Quarterly Results - Jun 2025)
Net Profit:
6 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 914 Million (Small Cap)

stock-summary
P/E

39.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.47%

stock-summary
Debt Equity

-0.56

stock-summary
Return on Equity

21.91%

stock-summary
Price to Book

9.69